Skip to main contentAI and Advanced
/
SUNPHARMA · NSEBSE SENSEX77,537.72+0.82%BSE |
NIFTY 5024,231.85+0.64%NSE |
NIFTY BANK57,495.9+0.45%NSE |
NIFTY IT30,673.05+0.79%NSE |
NIFTY AUTO29,301.75+0.40%NSE |
NIFTY FMCG47,863.25+0.82%NSE |
NIFTY PHARMA26,416+0.39%NSE |
NIFTY 50023,512.95+0.54%NSE |
SU
NSE · Equity shares · Biotechnology & Drugs4.00 · 0.21%
Sun Pharmaceutical Industries SUNPHARMA
NSE:INR 1,904
BSE:INR 1,944
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for SUNPHARMA
Analysis, reports, chat and Advanced access use the same ShareKeyX account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 1,900
Day rangeINR 1,890.3 — INR 1,911.6
52-week rangeINR 1,548 — INR 2,046.9
Volume8.94 L
Market cap4.66 L
P/E37.84
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)58,462.04
Net Income (INR Cr)11,479.42
Rev Growth (5 Year %)11.78
EPS Growth (5 Year %)30.74
P/E Ratio37.84
EPS50.33
Research path: Interpret Sun Pharmaceutical Industries's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
SUNPHARMASun Pharmaceutical Industries1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 1,08,785.22 | 92,100.58 | 85,499.65 |
| Accumulated Depreciation Total | -15,515.27 | -13,574.78 | -12,576.04 |
| Cash Equivalents | 4,269.48 | 6,971.82 | 6,843.08 |
| Other Liabilities Total | 1,499.64 | 860.96 | 914.46 |
| Accrued Expenses | 2,524.23 | 1,885.58 | 1,688.91 |
| Long Term Debt | 31.26 | 2.52 | 1.33 |
| Common Stock Total | 239.93 | 239.93 | 239.93 |
| Other Equity Total | 11,601.59 | 7,989.43 | 7,096.43 |
| Other Current Assets Total | 114.7 | 1,465.98 | 355.46 |
| Prepaid Expenses | 458.91 | 374.99 | 413.54 |
| Total Assets | 1,08,785.22 | 92,100.58 | 85,499.65 |
| Current Portof LT Debt/Capital Leases | 207.1 | 151.27 | 125.69 |
| Additional Paid-In Capital | 1,187.41 | 1,187.41 | 1,187.41 |
| Cash | 5,501.03 | 3,296.95 | 2,442.57 |
| Total Equity | 83,570.09 | 72,218.02 | 63,666.75 |
| Long Term Investments | 3,791.81 | 4,758.15 | 6,501.58 |
| Retained Earnings(Accumulated Deficit) | 69,840.95 | 61,825.79 | 54,118.5 |
| Total Common Shares Outstanding | 239.93 | 239.93 | 239.93 |
| Property/Plant/Equipment Total-Gross | 28,010.03 | 24,845.06 | 23,876.09 |
| Tangible Book Valueper Share Common Eq | 250.86 | 226.14 | 193.24 |
| Goodwill Net | 9,833.08 | 8,939.42 | 8,568.99 |
| Total Liabilities | 25,215.13 | 19,882.56 | 21,832.9 |
| Total Debt | 4,627.32 | 2,362.19 | 3,273.67 |
| Short Term Investments | 23,763.76 | 14,764.19 | 9,827.87 |
| Cashand Short Term Investments | 33,534.27 | 25,032.96 | 19,113.52 |
| Total Receivables Net | 17,693.9 | 14,960.8 | 13,255.7 |
| Notes Payable/Short Term Debt | 4,027.33 | 1,852.66 | 2,844.36 |
| Deferred Income Tax | 390.91 | 201.2 | 171.86 |
| Accounts Receivable-Trade Net | 15,562.19 | 13,122.51 | 11,302.97 |
| Property/Plant/Equipment Total-Net | 12,494.76 | 11,270.28 | 11,300.05 |
| Minority Interest | 309.65 | 267.93 | 3,459.19 |
| Total Current Liabilities | 22,622.04 | 18,194.21 | 16,983.77 |
| Total Inventory | 12,058.51 | 10,759.33 | 10,294.89 |
| Accounts Payable | 7,333.8 | 6,184.34 | 5,653.3 |
| Other Currentliabilities Total | 8,529.58 | 8,120.36 | 6,671.51 |
| Total Long Term Debt | 392.89 | 358.26 | 303.62 |
| Intangibles Net | 13,546.16 | 9,020.54 | 8,732.99 |
| Other Long Term Assets Total | 4,835.35 | 4,618.23 | 4,235.94 |
| Note Receivable-Long Term | 423.77 | 899.9 | 2,726.99 |
| Unrealized Gain(Loss) | 700.21 | 975.46 | 1,024.48 |
| Total Current Assets | 63,860.29 | 52,594.06 | 43,433.11 |
| Capital Lease Obligations | 361.63 | 355.74 | 302.29 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio4.09
Price to Sale Ratio7.98
Growth
Debt 5Yr CAGR %3.65
Margins
Operating Margin 12m21.77
Operating Margin 5y Avg19.37
Net Profit Margin 12m19.83
Net Profit Margin 5y18.08
Yield
Dividend Yield %0.82
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskModerate risk
Board Risk20.4
Analyst consensus
ConsensusBuy
Consensus score1.97
Analyst opinions33
Strong Sell count1
Sell count2
Hold count1
Buy count20
Strong Buy count9
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
| Lupin | INR 2,395 | 1.10 L | 19.12 | — |
Shareholding
Ownership
- Promoter
- 54.48%
- FII
- 14.54%
- MF
- 12.84%
- Other
- 18.14%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Shares to buy or sell: Chandan Taparia of Motilal Oswal recommends three stocks to buy today - 24 July 2026Market news · 24 Jul 2026, 8:08 am
Shares to buy or sell: Chandan Taparia has recommended three stocks to buy today, 24 July 2026 - Manappuram Finance, Eicher Motors, and Sun Pharmaceutical Industries shares.
Shares to buy or sell: Chandan Taparia of Motilal Oswal recommends three stocks to buy today - 19 May 2026Market news · 19 May 2026, 8:22 am
Shares to buy or sell: Chandan Taparia has recommended three stocks to buy today, 19 May 2026 - Sun Pharmaceutical Industries, BSE and PB Fintech shares.
Shares to buy or sell: Chandan Taparia of Motilal Oswal recommends three stocks to buy today - 12 May 2026Market news · 12 May 2026, 8:34 am
Shares to buy or sell: Chandan Taparia has recommended three stocks to buy today, 12 May 2026 - Sun Pharmaceutical Industries, Fortis Healthcare and Grasim Industries.
Buy or sell: Sumeet Bagadia recommends three stocks to buy on Monday — 9 March 2026Market news · 7 Mar 2026, 7:18 am
Buy or sell: Sumeet Bagadia recommends three stocks to buy on Monday — Bharat Electronics, Sun Pharmaceutical Industries, and NTPC.
IT sector valuations turn attractive after AI sell-off: Emkay; Adds Infosys, HCL Tech; Exits Mphasis in portfolio resetMarket news · 26 Feb 2026, 1:23 pm
In its model portfolio, Emkay Global has added Indus Towers, SRF, Infosys, and HCL Technologies, while exiting Sun Pharmaceutical Industries, Gravita India and Mphasis. It has trimmed its positions in Maruti Suzuki India, Larsen & Toubro (L&T), and Craftsman Automation.
Buy or sell: Ganesh Dongre of Anand Rathi recommends three stocks to buy on Monday - 29 December 2025Market news · 28 Dec 2025, 11:24 am
Ganesh Dongre of Anand Rathi recommends three stocks to buy on Monday - Sun Pharmaceutical Industries, AU Small Finance Bank, and CG Power and Industrial Solutions.
Corporate actions
Events
- board MeetingsQuarterly Results
- annual General MeetingAGM
- dividendRs.5.0000 per share(500%)Final Dividend
- board MeetingsAudited Results & Final Dividend
- annual General MeetingPOM
- annual General MeetingPOM
- dividendRs.11.0000 per share(1100%)Interim Dividend
- board MeetingsQuarterly Results & Interim Dividend
ShareKeyX Community
Discussion and sentiment for Sun Pharmaceutical Industries
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and ShareKeyX AI.
Checking your ShareKeyX account…
Company profile
Business information
What the company does
Sun Pharmaceutical Industries Limited is an India-based specialty generic pharmaceutical company with a presence in specialty therapies, generics and consumer healthcare products. The Company's global specialty portfolio spans products in dermatology, ophthalmology, and onco-dermatologym, among others. The Company manufactures and markets a large basket of pharmaceutical formulations across chronic and acute therapies, including generic, branded generics, specialty and complex products, over-the-counter (OTC), antiretrovirals (ARV), Active Pharmaceutical Ingredients (API), and intermediates. Its portfolio spans multiple dosage forms, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids. Its marketed specialty portfolio includes Ilumya/ Ilumetri, Winlevi, Levulan Kerastick + BLU-U, Absorica LD, Odomzo, Cequa, and others. Its portfolio also includes UNLOXCYTTM, an anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- SUNPHARMA
- BSE Code
- 524715
Questions
Stock FAQ
What is the symbol and ISIN of Sun Pharmaceutical Industries?
Sun Pharmaceutical Industries has the symbol SUNPHARMA and ISIN - INE044A01036.
What is the current price of Sun Pharmaceutical Industries?
Sun Pharmaceutical Industries is currently trading at INR 1,904.00.
What are the year high and year low of Sun Pharmaceutical Industries?
Sun Pharmaceutical Industries has a year high of INR 2,046.90 and a year low of INR 1,548.00.
What is the market capitalization of Sun Pharmaceutical Industries?
Sun Pharmaceutical Industries has a market capitalization of INR 4.66 lakh crore.
What is the P/E ratio of Sun Pharmaceutical Industries?
Sun Pharmaceutical Industries has a P/E ratio of 37.84.
What is the dividend yield of Sun Pharmaceutical Industries?
Sun Pharmaceutical Industries has a dividend yield of 0.82%.
How is the financial performance of Sun Pharmaceutical Industries based on revenue, net income, and EPS?
Sun Pharmaceutical Industries has revenue of INR 58,462.04 crore, net income of INR 11,479.42 crore, and EPS of INR 51.31.
What is the book value of Sun Pharmaceutical Industries?
Sun Pharmaceutical Industries has a book value of NA.
What is the debt-to-equity ratio of Sun Pharmaceutical Industries?
Sun Pharmaceutical Industries has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Sun Pharmaceutical Industries?
Sun Pharmaceutical Industries has a price-to-book ratio of NA and a price-to-sales ratio of 7.98.
Corporate-action adjustment is provider-defined. ShareKeyX research and computed indicators are not investment advice.